Pharmacy Pearls: GLP-1 Receptor Agonists and SGLT2 Inhibitors – Comparison of CV Outcomes

Pharmacy Pearls: GLP-1 Receptor Agonists and SGLT2 Inhibitors – Comparison of CV Outcomes

June 29th, 2020 | Pharmacy Pearls

This edition of Pharmacy Pearls compares the CV outcome study characteristics and results for both the glucagon-like peptide-1 receptor agonist (GLP-1 RA) and sodium glucose cotransporter 2 (SGLT2) inhibitor classes of medications.  It also summarizes key points in regard to the newer oral GLP-1 RA, Rybelsus®, as well as a listing of expanded indications for the SGLT2 inhibitor class of medications.  As a reminder, the first line approach for the treatment of type 2 diabetes remains metformin + lifestyle.  You can view AHP’s best practices for management of type 2 diabetes by clicking here.

As always, we welcome any questions or feedback you may have.  Just email the Pharmacy Team.

Loader Loading...
EAD Logo Taking too long?

Reload Reload document
| Open Open in new tab

Download PDF [867.98 KB]